Navigation Links
Oncothyreon reports full year and fourth quarter 2008 financial results
Date:3/9/2009

nd manufacturing expenses to $23.0 million from $12.6 million, partially offset by a decrease in general and administrative expenses to $9.7 million from $11.8 million. The $10.4 million increase in combined research and development and manufacturing expenses primarily relates to the bulk sale of inventory to Merck KGaA in December 2008, resulting in a significant increase in cost of sales. The $2.0 million decrease in general and administrative expense for 2008 compared to 2007 was primarily attributable to higher legal, accounting and tax advisory fees incurred in 2007 associated with the Company's reincorporation in Delaware.

As of December 31, 2008, Oncothyreon's cash, cash equivalents and short-term investments were $19.2 million, compared to $24.2 million at the end of 2007, a decrease of $5.0 million. The decrease was primarily the result of the use of cash to fund operations, offset by cash received from the license of Stimuvax manufacturing rights and know-how and the sale of inventory to Merck KGaA.

Financial Guidance

Oncothyreon believes the following financial guidance to be correct as of the date provided. The Company is providing this guidance as a convenience to investors and assumes no obligation to update it.

Expenses in 2009 are expected to be substantially less than in 2008, primarily as a result of transferring manufacturing and process development activities for Stimuvax to Merck KGaA and of the previously announced plan to restrict development activities to PX-478 and PX-866. Oncothyreon currently expects cash used in operations in 2009 to be approximately $12 million. As a result, Oncothyreon estimates that the Company's existing cash, together with a milestone payment from Merck KGaA expected at year end, will be sufficient to fund operations for at least the next twelve (12) months.

Conference Call and Webcast

Oncothyreon's management will discuss th
'/>"/>

SOURCE Oncothyreon Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Oncothyreon announces webcast of fourth quarter and year end 2008 financial results conference call
2. Oncothyreon to present at BIO CEO & Investor Conference 2009
3. Oncothyreon reports third quarter 2008 financial results
4. Oncothyreon to present at Rodman & Renshaw Annual Global Investment Conference
5. Oncothyreon announces November 6th webcast of third quarter 2008 financial results and corporate update conference call
6. Oncothyreon to present at BIO Investor Forum 2008
7. Oncothyreon announces receipt of NASDAQ letter regarding compliance with NASDAQ Global Market listing standards
8. Oncothyreon announces prioritization plan for development programs
9. Oncothyreon announces receipt of notice of non-compliance with market value of listed securities standard for listing on The NASDAQ Global Market
10. Oncothyreon initiates Phase 1 trial of PX-866 cancer compound
11. Oncothyreon initiates Phase 1b trial of PX-12 in patients with advanced metastatic cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... (PRWEB) December 17, 2014 Gene ... that it has entered into a technology access ... (ADM) to apply DNA2.0’s proprietary protein engineering technology, ... process. , “We are extremely excited that the ... platform. This proprietary bioengineering technology has now ...
(Date:12/17/2014)... SOUTH SAN FRANCISCO, Calif. , Dec. 17, ... positive results of a Phase 2 study evaluating ... for the treatment of patients with severe, chronic ... the current standard of care, including topical steroids ... endpoint was percent change in Visual Analog Scale ...
(Date:12/15/2014)...  GlassesOff Inc. (OTCBB: GLSO) announced today the appointment ... director of the Company,s Board of Directors. ... its CEO until its acquisition by Stanley Black ... Recognized as the inventor of the first Wi-Fi-based Active ... -based RFID solutions focused on improving operational efficiency, safety ...
(Date:12/13/2014)... (PRWEB) December 12, 2014 Clarassance, a ... announced its new name: Therabron Therapeutics , Inc. ... and bronchioles (a type of structure in the lungs ... company’s mission to develop novel protein therapeutics for the ... directors decided to change the name to mark the ...
Breaking Biology Technology:ADM and DNA2.0 Enter Into Protein Engineering Technology Access and Service Agreement 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 3Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 4AeroScout Founder Joins GlassesOff's Board of Directors 2AeroScout Founder Joins GlassesOff's Board of Directors 3Maryland-based Biotech Company's Path Forward in Treating Respiratory Diseases Sparks Name Change 2
... Wyeth,Pharmaceuticals, a division of Wyeth (NYSE: WYE ... the 63rd Annual Meeting of the American Society ... 100 mg/day or,150 mg/day of desvenlafaxine, a serotonin ... in moderate to severe,vasomotor symptoms (VMS) (hot flashes ...
... Cellmark Inc.,(Nasdaq: ORCH ), a leading worldwide ... third quarter 2007 financial results on,Thursday, November 1, ... hosting a,conference call and webcast to discuss the ... Management will discuss financial results for the third ...
... Technique to be Presented at American ... Meeting -, - Improved Techniques Could Lead to ... well as PGD with In Vitro Fertilization -, ... developing high throughput technologies that enable genome-wide,analyses, and Reprogenetics, ...
Cached Biology Technology:Study Data Results Showed Desvenlafaxine Significantly Reduced Moderate to Severe Vasomotor Symptoms in Menopausal Women Versus Placebo 2Study Data Results Showed Desvenlafaxine Significantly Reduced Moderate to Severe Vasomotor Symptoms in Menopausal Women Versus Placebo 3Study Data Results Showed Desvenlafaxine Significantly Reduced Moderate to Severe Vasomotor Symptoms in Menopausal Women Versus Placebo 4Study Data Results Showed Desvenlafaxine Significantly Reduced Moderate to Severe Vasomotor Symptoms in Menopausal Women Versus Placebo 5Orchid Cellmark to Announce Third Quarter 2007 Financial Results on November 1, 2007 2Empire Genomics and Reprogenetics Join Forces to Improve Preimplantation Genetic Diagnosis (PGD) 2Empire Genomics and Reprogenetics Join Forces to Improve Preimplantation Genetic Diagnosis (PGD) 3
(Date:12/15/2014)... DUBLIN , Dec. 12, 2014 Research ... announced the addition of the "Global Facial ... http://photos.prnewswire.com/prnh/20130307/600769 ... the identification of individuals. Facial recognition system measures ... as nose, jaw edges, mouth, and the distance ...
(Date:12/11/2014)... SALEM, N.C. , Dec. 10, 2014  That blood ... for quite a while. Hypertension – the medical term for ... in the early 1800s, and the inflatable cuff that,s used ... That doesn,t, however, mean there,s nothing new about hypertension, its ... some long-held beliefs about the condition and the best ways ...
(Date:12/10/2014)... 9, 2014  Valencell, a leader in performance biometric ... staggering demand from its licensees for highly accurate, clinically ... not solely coming from fitness and health sectors, but ... "A wearable is only as useful as the biometric ... ultimate driver in long-term mass consumer adoption of wearable ...
Breaking Biology News(10 mins):Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 3Research points to need for new approaches to treatment of high blood pressure 2Research points to need for new approaches to treatment of high blood pressure 3Research points to need for new approaches to treatment of high blood pressure 4Wearable Technology Products Demand Highly Accurate Biometric Technology 2
... A new study by the Wildlife Conservation Society, ... that habitat fragmentation and the addition of makeshift perches ... preferred habitat for common ravens that threaten sensitive ... The study appears in the January issue of the ...
... Renewable Energy Laboratory (NREL) have discovered that an enzyme from ... the Kamchatka Peninsula in Russia in 1990 can digest cellulose ... enzyme on the market. If the enzyme continues to ... the price of making lignocellulosic fuels, from ethanol to other ...
... 2014 -- Although drugs have been developed that inhibit the ... which causes many brain disorders and nervous system diseases ... work has not yet been fully explained. Now, ... as a model, have deciphered the mode by which the ...
Cached Biology News:Might more ravens -- aided by humans -- mean 'nevermore' for sage-grouse? 2Might more ravens -- aided by humans -- mean 'nevermore' for sage-grouse? 3NREL finds a new cellulose digestion mechanism by a fast-eating enzyme 2NREL finds a new cellulose digestion mechanism by a fast-eating enzyme 3Neurotransmitters resarch can promote better drugs for brain disorders 2Neurotransmitters resarch can promote better drugs for brain disorders 3
...
...
SphingoStripsTM contain fifteen different biologically active, nitrocellulose-immobilized lipids at 100 pmol per spot, which can be assayed for protein binding and specificity using a simple blot ove...
The Discovery Series PDQuest 2-D analysis software is used for imaging, analyzing, and databasing two-dimensional electrophoretic gels. The version upgrade allows upgrade of an established version of...
Biology Products: